Non-islet cell tumor hypoglycemia caused by intrathoracic solitary fibrous tumor: a case report

Masahiro Kitada¹*, Shunsuke Yasuda¹, Nana Takahashi¹, Satoshi Okazaki¹, Kei Ishibashi¹, Satoshi Hayashi¹, Yoshinobu Ohsaki¹ and Naoyuki Miyokawa²

Abstract

Background: Non-islet cell tumor hypoglycemia (NICTH) is defined as a form of hypoglycemia caused by an extrapancreatic tumor. Solitary fibrous tumor (SFT) associated with hypoglycemia is rare.

Case presentation: A 76-year-old woman, who had frequently experienced hypoglycemic symptoms such as presyncope for the prior 6 months, visited our hospital to undergo detailed examinations. Her fasting glucose level was low at 49 mg/dl. The blood levels of IRI and C-peptide were also low at 0.2 μU/ml and 0.21 ng/ml, respectively. Chest computed tomography revealed a mass measuring 15 cm in the left thoracic cavity. Percutaneous needle biopsy yielded a diagnosis of intrathoracic SFT associated with NICTH. The tumor was removed by video-assisted thoracoscopic surgery. Histological examination showed a tumor composed of simple spindle-shaped cells with an irregular arrangement. Immunohistochemical staining was positive for CD34, bcl-2, and vimentin and negative for alpha SMA and mesothelin. These results confirmed the diagnosis of SFT. Her hypoglycemic symptoms resolved rapidly after surgery. The clinical course has since remained favorable with no signs of recurrence.

Conclusion: We report a case of non-islet cell tumor hypoglycemia caused by intrathoracic SFT. The high-molecular-weight IGF-II produced by the tumor has been regarded as the cause of NICTH.

Keywords: Solitary fibrous tumor, Non-islet cell tumor hypoglycemia, Hypoglycemia

Background

Non-islet cell tumor hypoglycemia (NICTH) is defined as hypoglycemia caused by an extrapancreatic tumor. NICTH can occur in patients with mesenchymal tumors, hepatocellular carcinomas, and other extrapancreatic tumors. Solitary fibrous tumor (SFT) associated with hypoglycemia is rare at approximately 4% [1, 2]. The high-molecular-weight IGF-II produced by the tumor has been regarded as the cause of NICTH [3, 4]. Herein, we report a case with a surgically treated intrathoracic SFT, diagnosed based on recurrent episodes of hypoglycemia.

Case presentation

A 76-year-old woman, who had frequently experienced hypoglycemic symptoms such as presyncope for the prior 6 months, visited the internal medicine department of our hospital. Family history and past medical history were unremarkable. Physical examination showed a height of 155 cm, weight of 52 kg, blood pressure of 145/68 mmHg, and heart rate of 90 beats/min. There were no remarkable findings except for diminished breath sounds in the left middle and lower lobes of the lung. Her fasting glucose level was low, at 49 mg/dl. Her blood levels of IRI and C-peptide were also low at 0.2 μU/ml and 0.21 ng/ml, respectively. Chest radiography showed a huge mass in the left thoracic cavity (Fig. 1). Chest computed tomography revealed a mass measuring 15 cm with no invasion to the chest wall (Fig. 2). Positron emission tomography showed low FDG uptake in the intrathoracic mass (a low SUV) (Fig. 3). There were no lesions in other organs. Percutaneous needle biopsy was performed and SFT was thus diagnosed. The patient was diagnosed with intrathoracic SFT associated with...
NICTH and surgical treatment was planned. The tumor was removed by video-assisted thoracoscopic surgery. The excised specimen was a lobulated mass measuring \(16 \times 15 \times 8\) cm (Fig. 4). Histological examination showed a tumor composed of simple spindle-shaped cells with an irregular arrangement (Fig. 5). Immunohistochemical staining was positive for CD34 (Fig. 6), bcl-2, and vimentin, and negative for alpha SMA, mesothelin, s-100. The diagnosis of SFT was thus confirmed. Her hypoglycemic symptoms resolved rapidly after surgery. The clinical course was favorable with no signs of recurrence.

Discussion
It is known that NICTH can occur in patients with mesenchymal-derived tumors, hepatocellular carcinomas, and other extrapancreatic tumors. Approximately 4% of SFTs are reportedly associated with hypoglycemia [1–4]. NICTH is defined as hypoglycemia caused by a non-beta islet cell tumor. This condition is often associated with excessive production of high-molecular-weight IGF-II from the tumor and suppressed levels of serum albumin and IGF-I [5, 6]. NICTH is diagnosed by detecting the presence of an extrapancreatic tumor and by excluding other diseases that can cause hypoglycemia, such as liver failure, adrenal failure, and insulinoma. Although testing of high-molecular-weight IGF-II from the tumor by the Western immunoblot method or gel-filtration is more accurate for establishing the diagnosis, these procedures often are not feasible in many routine clinical settings. Therefore, the diagnosis is frequently
made based on the clinical course. In the present case, although the production of high-molecular-weight IGF-II from the tumor was not demonstrated, we considered her hypoglycemia to be attributable to NICHTH because the patient had no other diseases that could have caused hypoglycemia (such as the aforementioned liver failure, adrenal failure, and insulinoma) and levels of IRI and C-peptide were low. Furthermore, her hypoglycemic symptoms resolved rapidly after resection of the tumor.

Insulin-like growth factors (IGFs) consist of IGF-I and IGF-II. IGF-I has important growth-promoting features while IGF-II has an insulin-like hypoglycemic effect. The normal-molecular-weight form of IGF-II is bound to IGF-binding protein, forming a trimer. On the other hand, in NICHTH, high-molecular-weight IGF-II produced by the tumor forms a dimer which tends to result in extravascular leakage and tissue penetration, leading to hypoglycemia [7].

Resection of the primary tumor is the first-line treatment for NICHTH [8]. When curative resection is difficult, chemotherapy aimed at downsizing the tumor is a potential treatment option. There are also reports describing treatment with steroids or growth hormone as being effective [9, 10]. Steroids are known to have an effect not only on glycogen degradation and gluconeogenesis but also on the inhibition of IGF-II production, although the underlying mechanism has yet to be elucidated [11]. Further investigations are required to clarify the mechanisms underlying the development of NICHTH.

Conclusion
We report a case of non-islet cell tumor hypoglycemia caused by intrathoracic SFT. The high-molecular-weight IGF-II produced by the tumor has been regarded as the cause of NICHTH.

Consent
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contribution
MK have operated this case and analyzed all data. SY, NT, SO, KI, SH and YO did the assistant of the operation. NM diagnosed the pathology of this case. All authors read and approved the final manuscript.

Author details
1 Department of Respiratory Center, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan.
2 Department of Clinical Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, Japan.

Received: 4 July 2015 Accepted: 5 April 2016
Published online: 09 April 2016

References
1. Briselli M, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer. 1981;47(11):2657–89.
2. Kalebi AY, Hale MJ, Wong ML, Hoffman T, Murray J. Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update review on the Doege-Potter syndrome. J Cardiothorac Surg. 2009;4:45. doi:10.1186/1749-8090-4-45.
3. Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol. 2010;221(3):300–7.
4. Rena O, Filosso PL, Papalia E, Molinatti M, Di Marzo P, Maggi G, Oliaro A. Solitary fibrous tumour of the pleura: surgical treatment. Eur J Cardiothorac Surg. 2001;19(2):185–9.
5. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;318(22):1434–40.
6. Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab. 1991;73(4):1696–702.
7. Bond JJ, Meka S, Baxter RC. Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to –6. J Endocrinol. 2000;165(2):253–60.
8. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13(8):640–58.

9. Tsuro K, Kojima H, Okimoto S, Yoshiji H, Fujimoto M, Umemura M, et al. Glucocorticoid therapy ameliorated hypoglycemia in insulin-like growth factor-ll-producing solitary fibrous tumor. Intern Med. 2006;45:525–9.

10. Holt RI, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med. 2003;20:3–15.

11. Bourcigaux N, Arnault-Ouary G, Christol R, Pépin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27(2):246–51.